Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 11:14:4855-4867.
doi: 10.2147/DDDT.S278588. eCollection 2020.

Indole: The After Next Scaffold of Antiplasmodial Agents?

Affiliations
Review

Indole: The After Next Scaffold of Antiplasmodial Agents?

Abdrrahman Shemsu Surur et al. Drug Des Devel Ther. .

Abstract

Malaria remains a global public health problem due to the uphill fight against the causative Plasmodium parasites that are relentless in developing resistance. Indole-based antiplasmodial compounds are endowed with multiple modes of action, of which inhibition of hemozoin formation is the major mechanism of action reported for compounds such as cryptolepine, flinderoles, and isosungucine. Indole-based compounds exert their potent activity against chloroquine-resistant Plasmodium strains by inhibiting hemozoin formation in a mode of action different from that of chloroquine or through a novel mechanism of action. For example, dysregulating the sodium and osmotic homeostasis of Plasmodium through inhibition of PfATP4 is the novel mechanism of cipargamin. The potential of developing multi-targeted compounds through molecular hybridization ensures the existence of indole-based compounds in the antimalarial pipeline.

Keywords: PfATP4; antimalarial agents; hemozoin inhibition; indole; multi-target approach.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The chemical structures of quinoline in quinine (1) and chloroquine (2), and the endoperoxide scaffold in (+)-artemisinin (3).
Figure 2
Figure 2
Non-essential structural features in TCMDC-134,281 (4a) which were moved in the design of TCMDC-134,281 (4b).
Figure 3
Figure 3
Chemical structures of dihydrousamabarensine (5a), isosungucine (5b), flinderoles A–C (6a6c), isoborreverine (7a) and dimethylisoborreverine (7b).
Figure 4
Figure 4
Chemical structures of (1R,3S)-8a and (1S,3R)-8a enantiomers of a spiroazepineindole derivative and cipargamin (8b).
Figure 5
Figure 5
Chemical structures of conjugated indole analogues; (A) The optimal length of the linker connecting the triazolyl or piperazinyl tether to isatin or 3-hydroxyindole various from ethyl to pentyl alkyl in isatin-chloroquine conjugates (9a9c); (B) Conjugates of indol-3-yl with quinoline (10a) or quinolinium (10b); (C) The chemical structures of cryptolepine (11a), ellipticine (11b) and 2,7-dibromocryptolepine (11c); (D) The chemical structure of tryptanthrin (12a), and its more soluble 3-methyl ester (12b) and 3-chloro (12c) derivatives.
Figure 6
Figure 6
Intercalation into the CG-rich sequence of DNA by cryptolepine (PyMOL was used to regenerate the picture from the crystal structure with PDB accession number 1K9G). Cyan color: cryptolepine (19).
Figure 7
Figure 7
Chemical structures of aminoindole derivatives (13a13b), indole-3-glyoxyl tyrosine derivatives (14a14b), prenylated indole alkaloids (15a15c), and melatonin antagonist (16a16b).
Figure 8
Figure 8
Homology model of PfATP4 regenerated using the crystal structure of SERCA (PDB 3TLM) as a template.

Similar articles

Cited by

References

    1. World malaria report 2019. 2019. Available from: https://www.who.int/news-room/feature-stories/detail/world-malaria-repor.... Accessed October13, 2020.
    1. World malaria report 2018. 2019. Available from: https://www.mmv.org/newsroom/publications/world-malaria-report-2018. Accessed October13, 2020.
    1. Kumar S, Singh RK, Patial B, et al. Recent advances in novel heterocyclic scaffolds for the treatment of drug-resistant malaria. J Enzyme Inhib Med Chem. 2016;31(2):173–186. doi:10.3109/14756366.2015.1016513 - DOI - PubMed
    1. Kumar S, Bhardwaj TR, Prasad DN, et al. Drug targets for resistant malaria: historic to future perspectives. Biomed Pharmacother. 2018;104:8–27. doi:10.1016/j.biopha.2018.05.009 - DOI - PubMed
    1. Espinoza JL. Malaria resurgence in the Americas: an underestimated threat. Pathogens. 2019;8(1):11. doi:10.3390/pathogens8010011 - DOI - PMC - PubMed

MeSH terms